Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure - Full Text View

Sponsor:	Tottori University Hospital
Information provided by:	Tottori University Hospital
ClinicalTrials.gov Identifier:	NCT00663195

Purpose

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.

Condition	Intervention	Phase
Chronic Stable Heart Failure	Drug: spironolactone + furosemide	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Official Title:	Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure

Drug Information available for: Spironolactone Furosemide

U.S. FDA Resources

Further study details as provided by Tottori University Hospital:

Primary Outcome Measures:

MMP levels [ Time Frame: 16 weeks ]

Enrollment:	16
Study Start Date:	January 2004
Study Completion Date:	December 2005

Intervention Details:

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks

Detailed Description:

Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

chronic stable heart failure

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Responsible Party:	Center for Clinical Residency Program, Tottori University Hospital ( Kazuhide Ogino )
Study ID Numbers:	#344
Study First Received:	April 18, 2008
Last Updated:	April 18, 2008
ClinicalTrials.gov Identifier:	NCT00663195 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Tottori University Hospital:

heart failure
fibrosis
MMP
spironolactone
furosemide

Additional relevant MeSH terms:

Heart Failure
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Diuretics
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Agents
Furosemide

Pharmacologic Actions
Spironolactone
Membrane Transport Modulators
Aldosterone Antagonists
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Sodium Potassium Chloride Symporter Inhibitors

ClinicalTrials.gov processed this record on November 27, 2009